Angiotech Announces Changes to Management and Board of Directors
Angiotech Pharmaceuticals, Inc. announced that its shareholders and Board of Directors have approved changes to the Company's executive management team and Board of Directors.
Effective October 8 , Thomas Bailey and Angiotech mutually agreed that Mr. Bailey would transition from his current role as President and CEO of Angiotech, and into a Board role. As of that same date, at the Company's Annual General Meeting, Mr. Bailey was elected by the Company's shareholders to serve on Angiotech's Board of Directors. In addition, Kurt Cellar , Jeffrey Goldberg , Don Casey , Bradley Karro and Omar Vaishnavi were also re-elected to the Board of Directors.
Mr. Victor Diaz , who has been named President and Chief Operating Officer, and Ms. Tammy Neske , Chief Business Officer, will report to the Board of Directors, and their respective roles and responsibilities will remain generally unchanged. Mr. Jay Dent will continue to serve as Senior Vice President and Chief Financial Officer.
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
